View Item 

Show simple item record

Nesiritide: Harmful or Harmless?

dc.contributor.authorDorsch, Michael P.en_US
dc.contributor.authorRodgers, Jo Ellenen_US
dc.date.accessioned2012-03-16T16:00:06Z
dc.date.available2012-03-16T16:00:06Z
dc.date.issued2006-10en_US
dc.identifier.citationDorsch, Michael P.; Rodgers, Jo Ellen (2006). "Nesiritide: Harmful or Harmless?." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 26(10). <http://hdl.handle.net/2027.42/90328>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90328
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.subject.otherNesiritideen_US
dc.subject.otherVasodilator Therapy. (Pharmacotherapy 2006;26(10):1465–1478)en_US
dc.subject.otherAcute Decompensated Heart Failureen_US
dc.titleNesiritide: Harmful or Harmless?en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmacy Services, University of Michigan Hospitals and Health Clinics, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherbureau for Scios, Inc., Fremont, California.en_US
dc.contributor.affiliationotherUniversity of North Carolina School of Pharmacy, University of North Carolina, Chapel Hill, North Carolinaen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90328/1/phco.26.10.1465.pdf
dc.identifier.doi10.1592/phco.26.10.1465en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceSackner‐Bernstein JD, Kowalski M, Fox M, Aaronson KD. Short‐term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA 2005; 293: 1900 – 5.en_US
dc.identifier.citedreferenceJensen KT, Eishkjeen H, Carstens J, Pedersen E. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci 1999; 96: 5 – 15.en_US
dc.identifier.citedreferenceYoshirmura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991; 84: 1581 – 8.en_US
dc.identifier.citedreferenceWang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004; 110: 1620 – 5.en_US
dc.identifier.citedreferenceButler J, Emerman C, Peacock WF, et al, on behalf of the Vasodilation in the Management of Acute Heart Failure (VMAC) Investigators. The efficacy and safety of B‐type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated heart failure. Nephrol Dial Transplant 2004; 19: 391 – 9.en_US
dc.identifier.citedreferenceSackner‐Bernstein JD, Skopicki H, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487 – 91.en_US
dc.identifier.citedreferenceHeywood JT. Temporal characteristics of serum creatinine elevations in patients receiving nesiritide and nitroglycerin [abstr]. J Card Fail 2005; 11: S158.en_US
dc.identifier.citedreferenceHeywood JT. Combining nesiritide with high‐dose diuretics may increase the risk of increased serum creatinine [abstr]. J Card Fail 2005; 11: S154.en_US
dc.identifier.citedreferenceAbraham WT. Serum creatinine elevations in patient receiving nesiritide are related to starting dose [abstr]. J Card Fail 2005; 11: S156.en_US
dc.identifier.citedreferenceScios, Inc. Natrecor (nesiritide) product labeling. Fremont, CA; 2005.en_US
dc.identifier.citedreferenceYancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting: from the follow–up serial infusion of nesiritide (FUSION) I trial. Am J Cardiol 2004; 94: 595 – 601.en_US
dc.identifier.citedreferenceScios, Inc. Data on file. Fremont, CA; 2005.en_US
dc.identifier.citedreferencePeacock WF, Emerman CL, Silver MA, on behalf of the Prospective Randomized Outcomes Study of Acutely Decompensated Heart Failure Treated Initially as Outpatients with Nesiritide (PROACTION) Study Group. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure. Am J Emerg Med 2005; 23: 327 – 31.en_US
dc.identifier.citedreferencePeacock WF, Emerman CL, on behalf of the Prospective Randomized Outcomes Study of Acutely Decompensated Heart Failure Treated Initially as Outpatients with Nesiritide (PROACTION) Study Group. Safety and efficacy of nesiritide in the treatment of decompensated heart failure in observation patients [abstr]. J Am Coll Cardiol 2003; 41: 336A.en_US
dc.identifier.citedreferencePeacock WF, Emerman CL, Wynne J, on behalf of the Acute Decompensated Heart Failure National Registry (ADHERE) Scientific Advisory Committee and Investigators. Early use of nesiritide in the emergency department is associated with improved outcome: an ADHERE registry analysis [abstr]. Ann Emerg Med 2004; 44: S78.en_US
dc.identifier.citedreferenceChang R, Elatre WA, Heywood JT. Effect of nesiritide on length of hospital stay in decompensated heart failure. J Cardiovasc Pharmacol Ther 2004; 9: 173 – 7.en_US
dc.identifier.citedreferenceFonarow GC, Adams KF, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in‐hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005; 293: 572 – 80.en_US
dc.identifier.citedreferenceSilver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide vs dobutamine on short‐term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002; 39: 798 – 803.en_US
dc.identifier.citedreferenceLissovoy G, Stier DM, Ciesla G, et al. Economic implications of nesiritide vs dobutamine in the treatment of patients with acutely decompensated congestive heart failure. Am J Cardiol 2003; 9: 631 – 3.en_US
dc.identifier.citedreferenceGerhard T, Zineh I, Winterstein AG, Hartzema AG. Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure. Pharmacotherapy 2006; 26: 34 – 43.en_US
dc.identifier.citedreferenceArnold LM, Crouch MA, Carroll NV, Oinonen MJ. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure. Pharmacotherapy 2006; 26: 1078 – 85.en_US
dc.identifier.citedreferenceAmerican Heart Association, American Stroke Association. Heart disease and stroke statistics: 2006 update. Dallas, TX: American Heart Association, 2006. Available from http:www.americanheart.orgdownloadableheart113535864858055‐1026_HS_Stats06book.pdf. Accessed March 12, 2006.en_US
dc.identifier.citedreferenceChin MH, Golman L. Correlation of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med 1996; 156: 1814 – 20.en_US
dc.identifier.citedreferenceAdams KF, Lindenfeld J, Arnold JMO, et al. HFSA 2006 comprehensive heart failure guideline. J Card Fail 2006; 12: 10 – 38.en_US
dc.identifier.citedreferenceFrancis GS, Siegel R, Goldsmith SR, et al. Acute vasoconstrictor response to furosemide in patients with chronic congestive heart failure. Ann Intern Med 1985; 103: 1 – 6.en_US
dc.identifier.citedreferenceFett DL, Cavero PG, Burnett Jr JC. Low‐dose atrial natriuretic factor and furosemide in experimental acute congestive heart failure. J Am Soc Nephrol 1993; 4: 162 – 7.en_US
dc.identifier.citedreferenceIkram H, Chan W, Espiner EA, Nicholls MG. Hemodynamic and hormone response to acute and chronic furosemide therapy in congestive heart failure. Clin Sci 1980; 59: 443 – 9.en_US
dc.identifier.citedreferenceSchaer G, Covit AB, Laragh JH, Cody RJ. Association of hyponatremia with increased renin activity in chronic congestive heart failure: impact on diuretic therapy. Am J Cardiol 1983; 51: 1635 – 8.en_US
dc.identifier.citedreferenceBayliss J, Norell M, Canepa‐Anson R, et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987; 57: 17 – 22.en_US
dc.identifier.citedreferenceNeuberg GW, Miller AB, O'Connor CM, for the PRAISE Investigators. Prospective randomized amlodipine survival evaluation: diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002; 144: 31 – 8.en_US
dc.identifier.citedreferenceCuffe MS, Califf RM, Adams Jr KF, et al. Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME‐CHF) investigators. Short–term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541 – 7.en_US
dc.identifier.citedreferenceAbraham WT, Adams KF, Fonarow GC, et al. In‐hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications. J Am Coll Cardiol 2005; 46: 57 – 64.en_US
dc.identifier.citedreferenceScios, Inc. Natrecor (nesiritide) product labeling. Fremont, CA; 2001.en_US
dc.identifier.citedreferenceAbraham WT, Lowes BD, Freguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady‐state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998; 4: 37 – 44.en_US
dc.identifier.citedreferenceColucci WS, Elkayam U, Horton DP, et al, for the Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000; 343: 246 – 53.en_US
dc.identifier.citedreferencePublication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for the treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287: 1531 – 40. (Erratum in JAMA 2002;288:577.).en_US
dc.identifier.citedreferenceBurger AJ, Horton DP, LeJemtel T, et al. Prospective randomized evaluation of cardiac ectopy with dobutamine or natrecor therapy: effect of nesiritide (B‐type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure–the PRECEDENT study. Am Heart J 2002; 144: 1102 – 8.en_US
dc.identifier.citedreferenceVan Der Zander K, Houben AJ, Hofstra L, et al. Hemodynamic and renal effects of low‐dose brain natriuretic peptide infusion in humans: a randomized, placebo‐controlled crossover study. Am J Physiol Heart Circ Physiol 2003; 285: H1206 – 12.en_US
dc.identifier.citedreferenceHolmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993; 76: 91 – 6.en_US
dc.identifier.citedreferenceLaVilla G, Fronzaroli C, Lazzeri C, et al. Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man. J Clin Endocrinol Metab 1994; 78: 1166 – 71.en_US
dc.identifier.citedreferenceJensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 1998; 274: F63 – 72.en_US
dc.identifier.citedreferenceMcGregor A, Richards M, Espiner E, et al. Brain natriuretic peptide administered to man: actions and metabolism. J Clin Endocrinol Metab 1990; 70: 1103 – 7.en_US
dc.identifier.citedreferenceLainchbury JG, Richards AM, Nicholls MG, et al. The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. Hypertension 1997; 30 ( 3 pt 1): 398 – 404.en_US
dc.identifier.citedreferenceMarcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double‐blind, placebo‐controlled, randomized crossover trial. Circulation 1996; 94: 3184 – 9.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.26.10.1465.pdf
Size:
101.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.